Targeting CD22 for the Treatment of B-Cell Malignancies
Author:
Publisher
Informa UK Limited
Subject
Immunology,Immunology and Allergy
Reference50 articles.
1. 2016 US lymphoid malignancy statistics by World Health Organization subtypes
2. R-CHOP Versus (vs) CHOP Followed by Maintenance Rituximab (MR) Vs Observation In Older Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Long-Term Follow-up of Intergroup E4494/C9793
3. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
4. Epratuzumab in the therapy of oncological and immunological diseases
5. A Role in B Cell Activation for CD22 and the Protein Tyrosine Phosphatase SHP
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. From mechanism to therapy: the journey of CD24 in cancer;Frontiers in Immunology;2024-05-31
2. Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma;Frontiers in Oncology;2024-04-22
3. Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22;Molecular Therapy: Oncology;2024-03
4. Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency;Journal of Clinical Investigation;2024-02-20
5. ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies;Molecular Cancer Therapeutics;2024-02-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3